Lilly retatrutide lawsuits: 11 filed, one dismissed

State of play on 9 October 2026: Eli Lilly has filed 11 retatrutide lawsuits since August, six on 12 August and five on 8 October. One, against Aesthetic Envy, was dismissed with prejudice on 11 September, so ten are open. No court has ruled on the merits of any.

New on 8 October: five complaints in four federal districts, reaching Louisiana and Arizona for the first time. A week before the filing, a retatrutide rating site scored a shop trading as American Peptides 100/100. This page covers the October cases, where the August cases stand, the appeal Lilly argued on 24 September and a Washington Post report on compounding pharmacies. The August wave of five FDA warning letters and six suits is in FDA's August letters and Lilly's six lawsuits.

Who did Lilly sue on 8 October 2026?

Bloomberg Law reported the filings the same morning. We found no Lilly press release for this wave.

Two identifications rest on records outside the complaints, which were not public on 9 October:

• Southlake Mhya PLLC. Bloomberg Law names the defendant as Medrein Health & Aesthetics. The federal NPI registry lists the PLLC as doing business under that name at a Southlake, Texas address, inside the Fort Worth division where the case was filed. We do not know which products or pages the complaint cites.
• American Peptides L.L.C. americanpeptides.us sells retatrutide as "RETA-GLP3" in 10 to 60 mg vials, and its safety data sheet gives a Shreveport street address, matching the court division. We have not confirmed from the filing that the suit targets this website. A separate site, americanpeptides.com, runs a wholesale program; we found nothing tying it to the LLC. On 9 October the americanpeptides.us retatrutide page still loaded with five certificates listed.

Cenexa Labs' site search returned no retatrutide product on 9 October. We have no capture from before the filing, so we cannot say whether a page came down.

What does the LiveWell complaint cite as evidence?

The same kinds of evidence as the August complaints. Lilly pleads state-law unfair-competition and consumer-protection counts, in federal court on diversity grounds, and asks for a permanent injunction against selling anything containing or claiming to contain retatrutide, plus damages, disgorgement of profits and fees. Its exhibits:

1. Bac water sold beside the vial. The product page tells buyers to "[r]econstitute with bacteriostatic water" and links to the shop's own bac water "for peptide reconstitution". Lilly argues a real lab "would have its own protocols and reagents".
2. A manufacturing claim. LiveWell describes a "cGMP-certified facility" at a downtown Dallas address. The complaint says that address is a high-rise office building and cites the landlord's leasing page.
3. Customer and influencer posts. Facebook posts from buyers attributing weight loss to the products, a TikTok creator with a 20%-off affiliate code, and shop replies saying it was "proud of [their] progress".
4. Lifestyle copy. Posts telling buyers to "[t]ake back control of your health", which Lilly sets against the research-use-only label.
5. Reddit threads about harm. The complaint quotes r/Retatrutide and r/Biohacking posts on hospital visits, skin reactions and a thread titled "Bacteria and endotoxins". None of those posts names LiveWell.

One number moved. The August complaints said FDA had sent "at least 16 warning letters related to retatrutide"; the LiveWell complaint says "at least 21". That count is Lilly's, and we have not reconciled it with FDA's database.

Where do the six August cases stand?

Undecided on the merits. Three things happened on the dockets:

The Aesthetic Envy docket also shows the case was filed in the Eastern District of California, not the Northern District named in Lilly's August release.

Legendary's motion opens: "Lilly does not sell retatrutide, and on its own allegations it cannot." It argues that Lilly's lost-sales theory rests on two anonymous Reddit posts that do not mention Legendary, and that Texas does not recognise the common-law claim Lilly pleaded. Every complaint we have read rests on the same lost-sales theory, so a win for Legendary would bear on the other cases.

What is Lilly v. Kennedy, and why does it matter for retatrutide?

It is Lilly's separate fight with FDA over whether retatrutide is a biologic, which decides how the drug is regulated after approval. No ruling had issued by 9 October.

FDA refused Lilly's request to designate retatrutide a "biological product". Under 21 CFR 600.3(h)(6) a protein must be more than 40 amino acids. FDA's appeal brief (15 May 2026) says retatrutide has a chain of 39 alpha amino acids plus an attached two-residue chain, at least one of which is not an alpha amino acid, so by FDA's count it has 40 at most. Lilly's brief (1 April 2026) argues FDA should count all of them, and that FDA missed a 60-day statutory deadline to decide.

Two consequences turn on the answer:

• Exclusivity. A biologic gets 12 years before a biosimilar can be approved (42 U.S.C. 262(k)(7)); a new chemical entity gets 5 years of data exclusivity.
• Compounding. FDA's guidance on biological products says the 503A and 503B compounding exemptions do not apply to biologics, so a biologic designation would keep pharmacies from compounding retatrutide after approval too.

Nothing here changes the position of a research vial today. FDA already says retatrutide cannot be compounded, and the ruling governs approved product.

What did the Washington Post report on 7 October?

That the administration is drafting a plan to allow the "temporary sale" of some previously restricted peptides through compounding pharmacies while regulators write new rules. The Post cites people who spoke on condition of anonymity and says the plan has not been announced, the timing is unclear and it could change. HHS did not comment. We read the report through a syndicated copy and Becker's summary.

What we could confirm:

• The pharmacy trade group APC says it met FDA twice to ask for interim enforcement discretion, with patient disclosures, serious adverse-event reporting and data collection as conditions.
• A Federal Register search on 9 October returned no notice on peptides or the 503A bulks list since 20 September.
• The peptides FDA's advisory committee reviewed in July were BPC-157, KPV, TB-500, MOTS-c, Semax, epitalon and emideltide. Retatrutide was not among them (the FDA peptide vote).

A plan like the one reported would cover pharmacy compounding on a prescription. It would not cover a vial sold for research use or touch the retatrutide suits.

What did a rating site say about American Peptides?

It scored American Peptides 100/100. On 1 October 2026 retaradar.com ranked it second of 24 retatrutide sellers, and on 9 October, a day after the filing, the page still showed 100/100 with no mention of the lawsuit. We have not confirmed from the complaint that the suit concerns this website.

The review checked documents closely. It matched five Bioviridian certificates on the lab's own site and noted that the lab copies carried a later issue date than the vendor copies, that one lab copy named the sample "Retatrutide 100mg" where the vendor copy said 10 mg, and that Trustpilot reviews arrived in bursts on 30 September. None of that lowered the score, because its six checks cover shipping, payment, quality claims, contact details, an outside rating and perks. retaradar also discloses that another vendor pays for its top spot.

None of the rating sites we checked scores legal exposure, and our own composite does not either; we report FDA letters and suits on vendor pages instead. A clean certificate tells you the vial matches the label, not whether the seller will be in court next week.

What should you check before ordering?

Start with our seven-point acceptance checklist. Three of its checks map onto what Lilly and FDA cite:

1. Search the dockets. Type the vendor's company name and "Eli Lilly" into CourtListener. It is free, and it listed all five October cases on the morning they were filed.
2. Search FDA's warning letter database for the company name and the domain.
3. Read the product page the way Lilly's lawyers do. Bac water linked from the vial page, mixing instructions, dosing calculators, code names and customer weight-loss posts all appear as evidence in these filings. Our code-name decoder lists the aliases.

Save every certificate for lots you hold with the date you retrieved it, and resolve each one on the lab's own site; when a seller stops trading, its certificate archive often goes with it. If a vendor publishes an endotoxin result, read the unit before the verdict (endotoxin on a peptide COA). For the one lawful route to retatrutide before approval, see where to buy retatrutide.

What we read

The CourtListener dockets for all eleven Lilly cases as of 9 October 2026, and the NPI registry entry for Southlake Mhya PLLC. The LiveWell complaint in full. The Aesthetic Envy dismissal notice. The Legendary Peptides motion to dismiss (introduction and argument headings). Both Seventh Circuit briefs in Lilly v. Kennedy, and the docket showing argument on 24 September. FDA's guidance on biological products and compounding. Lilly's 29 September release. The Washington Post report via syndication, and APC's statement. retaradar's American Peptides review on 1 and 9 October. The americanpeptides.us and cenexalabs.com sites on 9 October. This is a document review, not a first-hand audit.

What we did not read

The complaints against American Peptides, Cenexa Labs, MedShape and Southlake Mhya PLLC, which were not public on 9 October. Any answer from the October defendants. Lilly's response to the Legendary motion. The district court's December 2025 opinion in full (we rely on FDA's account of it). The argument audio in full. The Washington Post original behind its paywall. MedShape's and Medrein's websites for retatrutide listings.

Sources

• Eli Lilly v. American Peptides L.L.C., W.D. La. 5:26-cv-04146, docket
• Eli Lilly v. Cenexa Labs LLC, S.D. Tex. 4:26-cv-08806, docket
• Eli Lilly v. MedShape Weight Loss Clinic LLC, D. Ariz. 2:26-cv-07361, docket
• Eli Lilly v. LiveWell Peptides owner, N.D. Tex. 3:26-cv-03514, complaint, 8 Oct 2026
• Eli Lilly v. Southlake Mhya PLLC, N.D. Tex. 4:26-cv-01294, docket
• Eli Lilly v. Aesthetic Envy, E.D. Cal. 2:26-cv-02764, notice of voluntary dismissal, 11 Sep 2026
• Eli Lilly v. Legendary Peptides, E.D. Tex. 1:26-cv-00347, motion to dismiss, 2 Oct 2026
• Eli Lilly v. Kennedy, 7th Cir. 26-1301, Lilly opening brief, 1 Apr 2026
• Eli Lilly v. Kennedy, 7th Cir. 26-1301, FDA brief, 15 May 2026
• Seventh Circuit, oral argument audio, 24 Sep 2026
• FDA, Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved BLA (guidance)
• 21 CFR 600.3, definitions
• Eli Lilly, TRIUMPH-2 release with BLA timing, 29 Sep 2026
• Bloomberg Law, Eli Lilly sues more vendors, 8 Oct 2026 (secondary)
• The Washington Post, temporary sale of some unapproved peptides, 7 Oct 2026
• Becker's Hospital Review, summary of the Post report, 8 Oct 2026 (secondary)
• APC, peptide plan reportedly in the works, 9 Oct 2026
• retaradar, American Peptides review, checked 1 Oct 2026
• NPI registry, Southlake Mhya PLLC (doing business as Medrein Health and Aesthetics), checked 9 Oct 2026
• American Peptides, retatrutide safety data sheet